Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 8.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 16,181 shares of the medical equipment provider’s stock after selling 1,405 shares during the quarter. Kentucky Retirement Systems’ holdings in Hologic were worth $1,318,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC acquired a new position in Hologic in the 3rd quarter valued at about $25,000. Innealta Capital LLC purchased a new position in shares of Hologic in the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic during the 2nd quarter worth approximately $37,000. Finally, Cromwell Holdings LLC boosted its position in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HOLX. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Raymond James raised their target price on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Trading Up 0.2 %

Shares of Hologic stock opened at $78.79 on Tuesday. The company has a fifty day simple moving average of $80.63 and a 200-day simple moving average of $78.28. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The stock has a market cap of $18.30 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the company posted $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.